Adlai Nortye Ltd. - American Depositary Shares (ANL) is currently showing a neutral headline tone with a mixed / range backdrop. The latest news flow is being framed here as context rather than prediction, so beginners can quickly see whether headlines are helping, hurting, or complicating the chart story. Earnings tone is currently no clear earnings read.
HEADLINE TAKE: The current headline mix looks balanced, so the overall news tone reads neutral right now.
Change stock
Search another ticker to view its latest news page.
Full chart, indicators and drawing tools on TradingView. Move to Platforms when you are ready to act.
MyStockHarbor.com
NEWS SCORE
50/100
Neutral
Bearish
Neutral
Bullish
Earnings Tone
28
Weak based on actual EPS/revenue
Confidence
Low
Headline depth
Last Price
$10.63
Trend Context
Mixed / range
Latest briefing
What's happening with ANL
globenewswire.com13 Jul 2026
Adlai Nortye Expands Scientific Advisory Board with Appointment of Two Leading Medical Oncologists
SINGAPORE and NORTH BRUNSWICK, N.J., July 13, 2026 (GLOBE NEWSWIRE) -- Adlai Nortye Ltd. (NASDAQ: ANL) (“Adlai Nortye” or the “Company”), a clinical-stage biotechnology company focused on the development of innovative cancer therapies, today announced the expansion of its Scientific Advisory Board (SAB) with the appointments of two leading medical oncologists, Dr. David S. Hong and Dr. Piro Lito.
Article excerpt provided by the FMP news feed. AI is used only for the optional "Why this matters" read.Read full article ↗
globenewswire.com16 Apr 2026
Adlai Nortye Announces $150.0 Million Private Placement Equity Financing
SINGAPORE and NORTH BRUNSWICK, N.J., April 16, 2026 (GLOBE NEWSWIRE) -- Adlai Nortye Ltd. (Nasdaq: ANL) (the “Company” or “Adlai Nortye”), a clinical-stage biotechnology company focused on the development of innovative cancer therapies, today announced that it has entered into a securities purchase agreement for a private investment in public equity financing that is expected to result in gross proceeds of approximately $150.0 million, before deducting placement agent fees and other private placement expenses.
Article excerpt provided by the FMP news feed. AI is used only for the optional "Why this matters" read.Read full article ↗
zacks.com20 May 2026
Adlai Nortye Ltd. Sponsored ADR (ANL) Upgraded to Buy: Here's What You Should Know
Adlai Nortye Ltd. Sponsored ADR (ANL) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects.
Article excerpt provided by the FMP news feed. AI is used only for the optional "Why this matters" read.Read full article ↗
Older updates drop into a lighter feed
zacks.com
11 May 2026
Here's Why Adlai Nortye Ltd. Sponsored ADR (ANL) Is a Great 'Buy the Bottom' Stock Now
